Technology evaluation: colostrinin, ReGen
- PMID: 15732533
Technology evaluation: colostrinin, ReGen
Abstract
ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical